Rectal indomethacin doesn't prevent post- ERCP pancreatitis 7 April 2016 (HealthDay)—For patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), rectal indomethacin does not prevent the development of post-ERCP pancreatitis (PEP), according to a study published in the April issue of Gastroenterology. John M. Levenick, M.D., from the Penn State Hershey Medical Center, and colleagues conducted a prospective trial of 449 patients undergoing ERCP (about 70 percent at average risk for PEP). Patients were randomized to a single dose of rectal indomethacin or a placebo suppository (223 and 226 patients, respectively). Patients were followed for the primary outcome of the development of PEP. The researchers found that 7.2 and 4.9 percent of patients in the indomethacin and placebo groups, respectively, developed PEP (P = 0.33). Between the groups, complications and the severity of PEP were similar. The study was stopped early owing to futility per a priori protocol guidelines. "In a randomized controlled study of consecutive patients undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis," the authors write. More information: Abstract Full Text Copyright © 2016 HealthDay . All rights reserved. 1 / 2

Rectal indomethacin doesn't prevent post-ERCP pancreatitis · Title: Rectal indomethacin doesn't prevent post-ERCP pancreatitis Subject: Rectal indomethacin doesn't prevent post-ERCP

Download PDF Report

Upload
dokhuong
View
214
Download
0

Embed Size (px)

Citation preview

Page 1: Rectal indomethacin doesn't prevent post-ERCP pancreatitis · Title: Rectal indomethacin doesn't prevent post-ERCP pancreatitis Subject: Rectal indomethacin doesn't prevent post-ERCP

Rectal indomethacin doesn't prevent post-ERCP pancreatitis7 April 2016

(HealthDay)—For patients undergoing endoscopicretrograde cholangiopancreatography (ERCP),rectal indomethacin does not prevent thedevelopment of post-ERCP pancreatitis (PEP),according to a study published in the April issue of Gastroenterology.

John M. Levenick, M.D., from the Penn StateHershey Medical Center, and colleaguesconducted a prospective trial of 449 patientsundergoing ERCP (about 70 percent at averagerisk for PEP). Patients were randomized to a singledose of rectal indomethacin or a placebosuppository (223 and 226 patients, respectively).Patients were followed for the primary outcome ofthe development of PEP.

The researchers found that 7.2 and 4.9 percent ofpatients in the indomethacin and placebo groups,respectively, developed PEP (P = 0.33). Betweenthe groups, complications and the severity of PEPwere similar. The study was stopped early owing tofutility per a priori protocol guidelines.

"In a randomized controlled study of consecutivepatients undergoing ERCP, rectal indomethacin didnot prevent post-ERCP pancreatitis," the authorswrite.

More information: AbstractFull Text

1 / 2

https://medicalxpress.com/tags/patients/

https://medicalxpress.com/tags/randomized+controlled+study/

http://www.gastrojournal.org/article/S0016-5085(16)00004-4/abstract

http://www.gastrojournal.org/article/S0016-5085(16)00004-4/fulltext

http://www.healthday.com/

Page 2: Rectal indomethacin doesn't prevent post-ERCP pancreatitis · Title: Rectal indomethacin doesn't prevent post-ERCP pancreatitis Subject: Rectal indomethacin doesn't prevent post-ERCP

APA citation: Rectal indomethacin doesn't prevent post-ERCP pancreatitis (2016, April 7) retrieved 10July 2018 fromhttps://medicalxpress.com/news/2016-04-rectal-indomethacin-doesnt-post-ercp-pancreatitis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, nopart may be reproduced without the written permission. The content is provided for information purposes only.

2 / 2

https://medicalxpress.com/news/2016-04-rectal-indomethacin-doesnt-post-ercp-pancreatitis.html

http://www.tcpdf.org